These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30927733)

  • 21. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis.
    Adams A; Tilden W; Bestwick J; Holden D; Bianchi L; Smets I; Giovannoni G; Gnanapavan S
    Eur J Neurol; 2022 Sep; 29(9):2754-2760. PubMed ID: 35615966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neurofilament light chain: a diagnostic potential for multiple sclerosis].
    Spirin NN; Kiseleva EV; Spirina NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(6):115-119. PubMed ID: 39072576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin D and axonal injury in multiple sclerosis.
    Sandberg L; Biström M; Salzer J; Vågberg M; Svenningsson A; Sundström P
    Mult Scler; 2016 Jul; 22(8):1027-31. PubMed ID: 26462862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
    Eikelenboom MJ; Petzold A; Lazeron RH; Silber E; Sharief M; Thompson EJ; Barkhof F; Giovannoni G; Polman CH; Uitdehaag BM
    Neurology; 2003 Jan; 60(2):219-23. PubMed ID: 12552034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis.
    Tortorella C; Direnzo V; Taurisano P; Romano R; Ruggieri M; Zoccolella S; Mastrapasqua M; Popolizio T; Blasi G; Bertolino A; Trojano M
    Mult Scler; 2015 Apr; 21(4):396-401. PubMed ID: 25168208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
    Tortosa-Carreres J; Cubas-Núñez L; Quiroga-Varela A; Castillo-Villalba J; Ramió-Torrenta L; Piqueras M; Gasqué-Rubio R; Quintanilla-Bordas C; Sanz MT; Lucas C; Huertas-Pons JM; Miguela A; Casanova B; Laiz-Marro B; Pérez-Miralles FC
    Mult Scler Relat Disord; 2024 Aug; 88():105734. PubMed ID: 38909525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.
    Malmeström C; Haghighi S; Rosengren L; Andersen O; Lycke J
    Neurology; 2003 Dec; 61(12):1720-5. PubMed ID: 14694036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
    Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis.
    Mariotto S; Gajofatto A; Zuliani L; Zoccarato M; Gastaldi M; Franciotta D; Cantalupo G; Piardi F; Polo A; Alberti D; Sartori S; Zanusso G; Agrò L; Demurtas R; Sechi G; Sechi E; Monaco S; Ferrari S
    J Neurol; 2019 Jul; 266(7):1643-1648. PubMed ID: 30944980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
    Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
    Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
    Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of CSF NfL and tau in ALS.
    Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
    J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis.
    Monreal E; Ruiz PD; San Román IL; Rodríguez-Antigüedad A; Moya-Molina MÁ; Álvarez A; García-Arcelay E; Maurino J; Shepherd J; Cabrera ÁP; Villar LM
    Front Public Health; 2024; 12():1397845. PubMed ID: 38711771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.